Abstract Body

Background: DetermineTM HIV-1/2 Ag/Ab Combo (DC) is an FDA-approved 4th generation rapid test that can distinguish HIV antigen and antibody reactivity, but performance in the new HIV diagnostic algorithm has not been evaluated. Data on the performance of DC on whole blood from individuals in early phases of infection are limited. We evaluated the performance of DC with plasma and whole blood.

Methods: We tested two sets of samples with DC and compared results to previous data from the APTIMA RNA assay (Aptima), Abbott ARCHITECT (ARC), Multispot HIV-1/HIV-2 rapid test (MS), and OraQuick ADVANCE (OQ). The sets included a subset of 178 plasma samples collected in the STOP study, a multi-site, prospective study evaluating methods to detect acute infection and 54 sequential plasma samples from 12 seroconverters to which washed red blood cells were added to simulate whole blood at 40% hematocrit. The number of DC-reactive samples and days after the first positive Aptima were calculated for samples from seroconverters. Statistical analysis was done using the McNemar’s test.

Results: Among the STOP specimens, the 4th generation lab-based ARC detected 19 more infections than DC (p=0.0001) (Table). Of 107 ARC-positive samples, DC detected 52.6% of the acute infections (p<0.0001) and 98.6% of the established infections (p=1.00). DC also identified 93.3% of HIV established infections in plasma that were not detected with OQ using whole blood at the screening sites (p=0.0001).

Among seroconverters, of 54 Aptima-positive/ARC-positive/MS-neg or –indeterminate samples, DC was reactive in 52 (96.3%) of plasma and 36 (66.6%) of whole blood (p=0.003) and OQ was reactive in 14 (26%) in plasma. The reactivity of DC in whole blood was 17 Ag+, 2 Ag+Ab+, and 17 Ab+. Whole blood reactivity was delayed in 7/12 seroconverters compared with plasma. Overall, the median delay in reactivity with whole blood compared to plasma was two days.

Conclusions: DC used with plasma detected fewer specimens with acute HIV infection compared to an instrumented lab-based 4th generation as ARC. DC became reactive later with whole blood than with plasma, but earlier than OQ used with plasma, which may be partially due to detection of antigen in whole blood. Thus, if CLIA-waived, DC would likely represent an advantage over other rapid tests in detecting infections earlier in settings where lab-based testing is not feasible.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V